csirt@kutim:~/threat-intel/cve/CVE-2026-5845

Katalog CVE

CVSS 9.6 · Critical EPSS 0,48%

Kerentanan Authorization Bypass Through User-Controlled Key pada github enterprise server. Skor CVSS 3.1 9.6 (Critical) menurut NVD.

Deskripsi (NVD)

An improper authorization vulnerability in scoped user-to-server (ghu_) token authorization in GitHub Enterprise Server allows an authenticated attacker to access private repositories outside the intended installation scope, which can include write operations, via an authorization fallback that treated a revoked/deleted installation as a global installation context, which could be chained with token revocation timing and SSH push attribution to obtain and reuse a victim-scoped token. This vulnerability affected all versions of GitHub Enterprise Server prior to 3.21 and was fixed in versions 3.20.1, 3.19.5, 3.18.8, 3.17.14, 3.16.17, 3.15.21, and 3.14.26. This vulnerability was reported via the GitHub Bug Bounty program.

Rincian

Terbit di NVD
21 April 2026
Terakhir diubah
17 Juni 2026
Status NVD
Analyzed
CVSS 3.1
9.6 (Critical), sumber NVD
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:H/I:H/A:N · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-639: Authorization Bypass Through User-Controlled Key
EPSS (30 hari)
0,48% peluang dieksploitasi; lebih tinggi dari 39,6% CVE lain

Produk dan versi terdampak

VendorProdukVersi terdampak
github enterprise server Semua versi sebelum 3.14.26
github enterprise server Versi 3.15.0 hingga sebelum 3.15.21
github enterprise server Versi 3.16.0 hingga sebelum 3.16.17
github enterprise server Versi 3.17.0 hingga sebelum 3.17.14
github enterprise server Versi 3.18.0 hingga sebelum 3.18.8
github enterprise server Versi 3.19.0 hingga sebelum 3.19.5
github enterprise server Versi 3.20.0

> Data dari konfigurasi CPE di NVD.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:11 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.